Ever Fortune. AI Co. Ltd. celebrates double success! On the 22nd, it announced that its "EFAI Cardiosuite SPECT Myocardial Perfusion Agile Workflows" has been notified by the Health Sciences Authority (HAS) of Singapore to obtain a medical device license. Additionally, it has just signed a five-year sales contract with a foreign agent for 200 sets.
Ever Fortune. AI, which is gradually thriving, has obtained a total of 14 Taiwan TFDA, 10 US FDA, and 9 other countries' medical device market approvals, totaling 33 licenses. Benefiting from the certification and listing of its products, the company achieved a record high revenue of NT$21 million in March, a year-on-year increase of 407%. The cumulative revenue for the first quarter reached NT$52.9 million, with a year-on-year growth rate of 342%. Analysts are optimistic that the company may break the hundred-million mark in the first half of the year, setting a new annual revenue record.
Ever Fortune. AI stated that the "EFAI Cardiosuite SPECT Myocardial Perfusion Agile Workflows" can generate auxiliary reports based on quantitative color scale analysis of myocardial perfusion images, providing clinical medical professionals with a tool to quickly generate bullseye analysis reports for myocardial perfusion. Medical personnel can upload bullseye DICOM image files and use this product to view and analyze the results of myocardial perfusion imaging and provide reports on scanned images.
General Manager Li Yu-zheng stated that Ever Fortune. AI's overseas layout has gradually shown results since the beginning of this year. The five-year, 200-set agency contract for a single product in a single market belongs to the field of nuclear medicine, which will be very helpful for future revenue over the next five years. At the same time, based on this experience in overseas layout and sales, Ever Fortune. AI will quickly replicate this model in other markets and with other products, establishing Taiwan's medical artificial intelligence internationally.
Resource (Mandarin):
